7 completed, 5 unknown, 2 not yet recruiting. 14 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 7, Unknown 5, Not yet recruiting 2 |
| Phase 2 | 1 | Completed 1 |
Follow Vaccine Reaction: new trials by email Literature Review of Vaccine Reaction trials Research Report on Vaccine Reaction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) In-House Recombinant Hepatitis B (Bio Farma) vaccine, Registered Hepatitis B vaccine recombinant (Engerix-B) - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Not yet recruiting | PT Bio Farma | 540 | 2025-09-01 | 2025-06-06 |
| Optimal Timing of Hepatitis B Vaccination After Transplants hepatitis B vaccine - Transplant-Related Disorder, Hepatitis B Virus Infection | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1500 | 2025-06-01 | 2025-03-21 |
| Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech), VidPrevtyn® Beta vaccine (Sanofi/GSK) - Vaccine Reaction, COVID-19 | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 248 | 2023-05-16 | 2023-06-29 |
| Immunogenicity, Reactogenicity of Shingrix in SLE Shingrix, Placebo - Zoster, Systemic Lupus Erythematosus | Phase 3 | Unknown | Seoul National University Hospital | 63 | 2023-05-08 | 2023-08-21 |
| A Comparison of Safety and Immunogenicity of Rabies Pre Exposure Prophylaxis Regimen Between Gvt of India Approved and WHO Approved. Regimen 1, Regimen 2 - Vaccine Reaction | Phase 3 | Completed | Kempegowda Institute of Medical Sciences, Bangalore | 144 | 2023-04-03 | 2026-08-07 |
| Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants Eupolio - Poliomyelitis, Vaccine Reaction | Phase 3 | Completed | LG Chem | 2001 | 2023-01-10 | 2025-04-06 |
| Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children SARS-CoV-2 Protein Subunit Recombinant Vaccine, Active Comparator - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Completed | PT Bio Farma | 1050 | 2022-10-09 | 2025-06-03 |
| A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Grippol Quadrivalent, Grippol Plus - Influenza, Influenza A | Phase 3 | Completed | NPO Petrovax | 824 | 2022-09-21 | 2024-04-26 |
| Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children Influenza vaccine [inactivated] - Influenza, Influenza, Human | Phase 3 | Unknown | St. Petersburg Research Institute of Vaccines and Sera | 948 | 2022-01-19 | 2023-08-30 |
| Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination BNT162b2, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK - COVID-19, Vaccine Reaction | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 247 | 2021-12-08 | 2022-07-11 |
| One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. MTX-hold - Rheumatoid Arthritis, Autoimmune Diseases | Phase 3 | Completed | Seoul National University Hospital | 184 | 2021-10-01 | 2022-12-16 |
| Allergy and COVID-19 Vaccines COVID-19 Vaccines - Anaphylactic Reaction, Vaccine Reaction | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 117 | 2021-09-15 | 2026-09-17 |
| Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine Influenza vaccine [inactivated] - Influenza, Influenza, Human | Phase 2 / Phase 3 | Completed | St. Petersburg Research Institute of Vaccines and Sera | 450 | 2020-10-06 | 2023-05-22 |
| Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine Oral Polio Vaccine, Oral Cholera Vaccine - Vaccine Reaction | Phase 3 | Unknown | International Centre for Diarrhoeal Disease Research, Bangladesh | 579 | 2018-07-01 | 2022-03-31 |
Influenza, Human (4) · COVID-19 (2) · Hepatitis B (2) · Anaphylaxis (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Herpes Zoster (1) · Infections (1) · Lupus Erythematosus, Systemic (1) · Orthomyxoviridae Infections (1) · Poliomyelitis (1)
Virus Diseases (10) · Infections (9) · RNA Virus Infections (7) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · DNA Virus Infections (3) · Immune System Diseases (3) · Orthomyxoviridae Infections (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Connective Tissue Diseases (2) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Digestive System Diseases (2) · Hepadnaviridae Infections (2)
Influenza Vaccines (2) · 2019-nCoV Vaccine mRNA-1273 (1) · BNT162 Vaccine (1) · COVID-19 Vaccines (1) · Cholera Vaccines (1) · Engerix-B (1) · Grippol (1) · Hepatitis B Vaccines (1) · Poliovirus Vaccine, Oral (1) · Vaccines (1)
Assistance Publique - Hôpitaux de Paris (3) · PT Bio Farma (2) · Seoul National University Hospital (2) · St. Petersburg Research Institute of Vaccines and Sera (2) · Institute of Hematology & Blood Diseases Hospital, China (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Kempegowda Institute of Medical Sciences, Bangalore (1) · LG Chem (1) · NPO Petrovax (1)
France (3) · Russia (3) · South Korea (2) · Bangladesh (1) · China (1) · India (1) · Indonesia (1) · Philippines (1) · Thailand (1)
Asrawati Asrawati, MD (1) · Bernie Medise, MD (1) · Cahya Satria, MD (1) · Deekshith J Reddy, MBBS (1) · Dr. Firdausi Qadri, PhD (1) · Ellina Ruzanova (1) · Ellina Ruzanova, PhD (1) · Trisna Windiani, MD (1)
PMID 28468794, PMID 29572291, PMID 35930728, PMID 22520134, PMID 26349548, PMID 27154394, PMID 31823141, PMID 35216744, PMID 36136760, PMID 36249342, PMID 36971457, PMID 38710192